This inventor holds 3 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Annji Pharmaceutical Co., Ltd.. Active years: 2015-2022.
Company Filing History:
Years Active: 2015-2022
Title: Chao-Wu Yu: Innovator in Histone Deacetylase Inhibitors
Introduction
Chao-Wu Yu is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of histone deacetylase (HDAC) inhibitors. With a total of 3 patents to his name, his work has the potential to impact cancer treatment significantly.
Latest Patents
Chao-Wu Yu's latest patents focus on histone deacetylases (HDACs) inhibitors. These inhibitors are disclosed according to specific structural formulas, featuring moieties that include benzene rings and cyclohexane rings. The HDAC inhibitors exhibit cytotoxicity against various cancer cell lines, making them useful for treating tumors associated with the deregulation of histone deacetylase activity. His inventions are particularly relevant for treating conditions such as glioma, breast cancer, colon cancer, and several other types of cancer.
Career Highlights
Chao-Wu Yu is affiliated with Annji Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments for serious health conditions, particularly cancers that are challenging to treat.
Collaborations
Chao-Wu Yu collaborates with notable colleagues, including Ji-Wang Chern and Pei-Teh Chang. These partnerships enhance the research and development efforts at Annji Pharmaceutical Co., Ltd., fostering an environment of innovation and discovery.
Conclusion
Chao-Wu Yu is a key figure in the development of histone deacetylase inhibitors, with a focus on advancing cancer treatment. His contributions to the field are significant and demonstrate the potential of innovative pharmaceutical research.